Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00250744 · ClinicalTrials.gov registry record · Phase 2
Comparison of Aprepitant Versus Gabapentin in the Prevention of Delayed Nausea and Vomiting
A Phase 2 study, sponsored by New Mexico Cancer Research Alliance.
- Completed
- Registry status
- Phase 2
- Development phase
- 200
- Enrollment target
NCT00250744 is a Phase 2 study that has completed, run by New Mexico Cancer Research Alliance. The registered enrollment target is 200 participants.
The verdict
NCT00250744, a Phase 2 study, has completed, sponsored by New Mexico Cancer Research Alliance.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 200 participants
- Enrollment target
Study Summary
1. To compare the effectiveness of gabapentin (titrated to300mg TID days -2 to 5) with aprepitant (125mg on day 1 and 80mg on days 2 and 3) in the control of delayed nausea and vomiting associated with level 3, 4 or 5 emetogenic chemotherapy in patients who experienced delayed nausea and/or vomiting during their first cycle of chemotherapy. 2. To evaluate and compare the safety profile associated with each anti-emetic regimen. 3. To assess subject satisfaction with anti-emetic therapy.
Interventions
- DRUG Aprepitant vs. Gabapentin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2004-12 |
| Est. Completion | 2007-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00250744
The ClinicalTrials.gov registry entry for NCT00250744 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New Mexico Cancer Research Alliance, which has 66 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Aprepitant vs. Gabapentin is the first listed.
NCT00250744 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00250744 about?
NCT00250744 is a clinical study titled "Comparison of Aprepitant Versus Gabapentin in the Prevention of Delayed Nausea and Vomiting". 1. To compare the effectiveness of gabapentin (titrated to300mg TID days -2 to 5) with aprepitant (125mg on day 1 and 80mg on days 2 and 3) in the control of delayed nausea and vomiting associated with level 3, 4 or 5 emetogenic chemotherapy in patients who experienced delayed nausea and/or vomiting...
What is the current status of trial NCT00250744?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 200 participants. The study started on 2004-12. Estimated completion is 2007-09.
What interventions are being tested in trial NCT00250744?
The interventions under investigation include: Aprepitant vs. Gabapentin (DRUG).
Who is sponsoring clinical trial NCT00250744?
This trial is sponsored by New Mexico Cancer Research Alliance, which has 66 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.